Other substances

COV2-2381

An anti-RBD (SARS-CoV-2 Spike) human monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

COV2-2381 is a human monoclonal antibody identified in serum of a COVID-19 convalescent patient. It bound SARS-CoV-2 Spike RBD and neutralized the live virus in vitro (Zost et al., 2020a). The antibody protected rhesus macaques from SARS-CoV-2 infection (Zost et al., 2021b). It prevented weight loss, decreased viral burden, and reduced lung inflammation in a mouse model after a viral challenge. The Fc region of the antibody was demonstrated to be important for the therapeutic effect (Winkler et al., 2021).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection Spike protein Animal model In vitro Antibody	in vitro binding assay; Vero E6 cells; K18-hACE c57BL/6J mice; Syrian hamsters; SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020	38.64	The antibody prevented weight loss, decreased viral burden, and reduced lung inflammation in a mouse model after a viral challenge. The Fc region of the antibody was demonstrated to be important for the therapeutic effect.	Feb/12/2021
Potently neutralizing and protective human antibodies against SARS-CoV-2 Spike protein ACE2 Biophysical assay Animal model In vitro Antibody	in vitro binding assay; in vitro biophysical assay; Vero E6 cells; BALB/c mice; rhesus macaques; SARS-CoV-2 pseudovirus; SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2023	42.78	The antibody protected rhesus macaques from SARS-CoV-2 infection.	Jul/15/2020
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein Spike protein Novel compound Protein factor In vitro Antibody	Patient sera; Vero E6 cell; (VSV) SARS-CoV-2 Spike-pseudotyped virus; SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020	53.44	The antibody neutralized SARS-CoV-2 in vitro.	Jul/10/2020

AI-suggested references

Link	Publication date
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques	Jan/04/2022

Export (.csv)